Bionovo, Inc. (Nasdaq: BNVI) announced results from two independent physician surveys which showed MF101 could become first-line treatment for menopausal vasomotor symptoms (hot flashes). In both qualitative and quantitative studies, 124 physicians board certified in internal medicine or obstetrics and gynecology specializing in the treatment of menopause reported MF101, if approved, would be their drug of choice for the treatment of hot flashes.

More: continued here

This entry was posted on Saturday, March 15th, 2008 at 12:03 am and is filed under Endocrinology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.